Incorporating the recent capital rejig + 2023 Audio brutalities
06/06/23 -"While our material upside has been maintained, the c.7% lower target price is due to the delayed recovery for its lynchpin segment (i.e. Audio c.67% of FY22 sales) due to the uncertain macroeconomic ..."
Pages
63
Language
English
Published on
06/06/23
You may also be interested by these reports :
09/05/25
Sonova’s full-year results slightly exceeded market expectations, with robust growth across both segments. The promising FY2025-26 outlook was well ...
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...